Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
5
Neutral
4
Bullish
5
Bearish
11
Neutral
4
Bullish
31
Bearish
6
Neutral
0
Bullish
26
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Oxygenta Pharmaceutical Limited, formerly S S Organics Ltd, specializes in manufacturing anti-ulcerative and antibacterial drugs, alongside other pharmaceuticals.
The company engages in both contract manufacturing and independent production, supporting its revenue through strategic partnerships.
Oxygenta's production facilities are situated in Medak, Andhra Pradesh, focusing on bulk drugs, including quinolones, antiasthmatic, and anti-inflammatory medications.
Despite operational challenges, such as the 2015 fire accident, Oxygenta has resumed commercial production to stabilize its operations and market position.
Pharmaceuticals & Biotechnology
Pharmaceuticals
188 Cr
High Risk
0.0
36.7
—
—
110.25
43.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Oxygenta Pharmaceutical Ltd (OXYGENTAPH) is currently trading at 51.35 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Oxygenta Pharmaceutical Limited, formerly S S Organics Ltd, specializes in manufacturing anti-ulcerative and antibacterial drugs, alongside other pharmaceuticals. The company engages in both contract manufacturing and independent production, supporting its revenue through strategic partnerships. Oxygenta's production facilities are situated in Medak, Andhra Pradesh, focusing on bulk drugs, including quinolones, antiasthmatic, and anti-inflammatory medications. Despite operational challenges, such as the 2015 fire accident, Oxygenta has resumed commercial production to stabilize its operations and market position.
Over the past 52 weeks, Oxygenta Pharmaceutical Ltd has traded between a low of ₹43.00 and a high of ₹110.25. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Oxygenta Pharmaceutical Ltd has a market capitalization of approximately 188.28. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Oxygenta Pharmaceutical Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 188.28 Cr, Oxygenta Pharmaceutical Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Oxygenta Pharmaceutical Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Oxygenta Pharmaceutical Ltd is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
154.05 | 201 Cr | — | 17.63 | 0.00 | -148.86 | -9.23 | -11.80 | ||
10.27 | 200 Cr | — | 0.34 | 0.00 | -9.85 | -8.75 | -47.12 | ||
273.75 | 198 Cr | — | 6.46 | 0.00 | 14.29 | 16.99 | 12.01 | ||
64.99 | 189 Cr | 7.69 | 1.54 | 0.00 | 20.04 | 19.30 | 16.59 | ||
51.35 | 188 Cr | — | 0.00 | 0.00 | 41.16 | -26.02 | -14.69 | ||
149.00 | 183 Cr | 27.28 | 3.79 | 0.00 | 13.87 | 16.29 | 7.62 | ||
164.20 | 183 Cr | 18.87 | 3.34 | 0.00 | 17.67 | 20.78 | 12.61 | ||
| Median: 7 Co. | — | 149.00 | 189 Cr | 18.87 | 3.34 | 0.00 | 14.29 | 16.29 | 7.62 |
Board Meeting
Oxygenta Pharmaceutical Ltd postponed its Board meeting from 25 July 2026 to 27 July 2026. The Board will consider unaudited financial results for the quarter ended 30 June 2026, limited review report and other business.
Board Meeting
Oxygenta Pharmaceutical Ltd: Board meeting originally set for 25 July 2026 postponed to 27 July 2026 to consider and approve unaudited results for quarter ended 30 June 2026 and Limited Review Report.
Board Meeting
Oxygenta Pharmaceutical Ltd will hold a Board meeting on 2026-07-25 to consider and approve unaudited financial results and limited review for the quarter ended 30-06-2026.
Board Meeting
Oxygenta Pharmaceutical Ltd informed BSE that its Board will meet on 2026-07-25 to consider and approve unaudited financial results and limited review report for quarter ended 2026-06-30.
